KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Equity Ratio (2016 - 2026)

Fulgent Genetics' Equity Ratio history spans 12 years, with the latest figure at 0.9 for Q1 2026.

  • On a quarterly basis, Equity Ratio fell 3.03% to 0.9 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.9, a 3.03% decrease, with the full-year FY2025 number at 0.92, down 1.0% from a year prior.
  • Equity Ratio hit 0.9 in Q1 2026 for Fulgent Genetics, down from 0.92 in the prior quarter.
  • Over the last five years, Equity Ratio for FLGT hit a ceiling of 13.62 in Q4 2022 and a floor of 0.9 in Q1 2022.
  • Historically, Equity Ratio has averaged 1.66 across 5 years, with a median of 0.92 in 2024.
  • Biggest five-year swings in Equity Ratio: skyrocketed 1393.89% in 2022 and later tumbled 93.26% in 2023.
  • Tracing FLGT's Equity Ratio over 5 years: stood at 13.62 in 2022, then tumbled by 93.26% to 0.92 in 2023, then increased by 0.89% to 0.93 in 2024, then fell by 1.0% to 0.92 in 2025, then dropped by 1.46% to 0.9 in 2026.
  • Business Quant data shows Equity Ratio for FLGT at 0.9 in Q1 2026, 0.92 in Q4 2025, and 0.92 in Q3 2025.